KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

CRISPR Therapeutics AG (CRSP) Shares Outstanding (Diluted Average): 2022-2024

Historic Shares Outstanding (Diluted Average) for CRISPR Therapeutics AG (CRSP) over the last 3 years, with Dec 2024 value amounting to $84.4 million.

  • CRISPR Therapeutics AG's Shares Outstanding (Diluted Average) rose 7.12% to $91.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $91.3 million, marking a year-over-year increase of 7.12%. This contributed to the annual value of $84.4 million for FY2024, which is 6.49% up from last year.
  • Per CRISPR Therapeutics AG's latest filing, its Shares Outstanding (Diluted Average) stood at $84.4 million for FY2024, which was up 6.49% from $79.2 million recorded in FY2023.
  • In the past 5 years, CRISPR Therapeutics AG's Shares Outstanding (Diluted Average) registered a high of $84.4 million during FY2024, and its lowest value of $77.7 million during FY2022.
  • In the last 3 years, CRISPR Therapeutics AG's Shares Outstanding (Diluted Average) had a median value of $79.2 million in 2023 and averaged $80.4 million.
  • Data for CRISPR Therapeutics AG's Shares Outstanding (Diluted Average) shows a peak YoY rose of 6.49% (in 2024) over the last 5 years.
  • Over the past 3 years, CRISPR Therapeutics AG's Shares Outstanding (Diluted Average) (Yearly) stood at $77.7 million in 2022, then increased by 1.90% to $79.2 million in 2023, then climbed by 6.49% to $84.4 million in 2024.